Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
absent, absorbed, accident, Activase, Aerial, air, al, Alteplase, analog, Answer, antithrombin, arbitrage, array, articulated, ASA, Asia, AsparecTM, Banca, barrier, batch, BioScrip, Bipartisan, blockage, bona, brokerage, budgetary, Bureau, cease, Chase, Citigroup, classification, closure, coagulopathy, cohort, Commonwealth, Como, complement, Concert, concurrently, conflicting, Connecticut, Consta, construction, copay, CORAR, Council, counterfeit, creditor, cyber, Dana, defect, defibrotide, Defitelio, del, delisting, derecognition, deregistration, device, diagnostic, differentiated, diligence, discharge, disgorgement, dispersion, DNA, DNB, dossier, draft, DRG, dysfunction, edition, EDS, EEA, EN, endothelial, environmental, equitable, erosion, exiting, facial, Farber, faster, Fenner, fide, fiduciary, field, frame, fumarate, Gentium, Greece, Guaranty, Guardia, GvHD, Hatch, hematologic, hematology, hematopoietic, hemorrhage, heparin, hepatic, HHS, HIPAA, HITECH, HSCT, hydrochloride, hypotension, IMPD, imposition, incorrectly, Interbank, intrusion, ISO, Italian, Italy, JPMorgan, JumpStartTM, Korean, landscape, Latuda, Lavoro, leukopenia, LeukotacTM, living, London, lowest, LP, lurasidone, Lynch, Manual, median, Merrill, methodology, mixture, mobile, modality, molecule, morbidity, Morgan, mortgage, multinational, NADAC, NARP, narrow, narrower, Nazionale, norbert, notification, olanzapine, older, omission, optimal, OSA, outflow, overly, parallel, Perrigo, PHE, Pierce, plant, plasminogen, porcine, Portability, PRAC, pregnant, processing, quetiapine, reassessment, reauthorization, refinanced, refinancing, remanded, Renal, renamed, rescission, resolution, resume, riedel, risperidone, Royal, safeguard, satisfactorily, sBLA, scalable, Scheme, shut, sinusoidal, SK, Smith, SmPC, South, Southern, Spain, Stanley, stem, stringent, Sunovion, Switzerland, Symphony, syndicate, syndication, synergy, tender, tendered, Thrombate, tied, tissue, traditional, traditionally, tranche, transparency, transportation, understood, unfair, UNI, untendered, variation, vascular, vial, vigilance, Villa, VOD, voluntarily, voluntary, Wall, wastewater, Waxman, wholly, withheld, Xavion, younger, Zug
Removed:
Abbott, acquirer, amending, Anchen, article, bioequivalence, broader, Carol, complied, compulsive, confined, daily, delaying, discouraging, disruptive, dose, doubtful, Eastern, Elizabeth, forward, fragmented, Gamble, ground, hearing, KKR, Kohlberg, Longitude, momtazee, neurologic, obsessive, partly, persistent, placement, plasma, Plea, post, preventing, proliferation, promptly, proportion, ratable, registering, remove, repetitive, settle, Solvay, sublicensed, underwritten, uninsured, unwanted, Venture
Filing tables
Filing exhibits
- 10-K Annual report
- 10.24 Cash Bonus Plan-international 2014
- 10.32 Amendment 2 to Credit Agreement
- 21.1 Subsidiaries
- 23.1 Consent of KPMG, Independent Registered Public Accounting Firm
- 23.2 Consent of Ernst & Young, LLP, Independent Registered Public Accounting Firm
- 31.1 Certification of CEO Pursuant to Rules 13A-14(A) and 15D-14(A)
- 31.2 Certification of CFO Pursuant to Rules 13A-14(A) and 15D-14(A)
- 32.1 Certifications of CEO and CFO Pursuant to 18 U.s.c. Section 1350
- Download Excel data file
- View Excel data file
Related press release
JAZZ similar filings
Filing view
External links
Exhibit 23.1
Consent of KPMG, Independent Registered Public Accounting Firm
The Board of Directors
Jazz Pharmaceuticals plc:
We consent to the incorporation by reference in the registration statement (No. 333-186886) on Form S-8, the registration statement (No. 333-179075) on Form S-8, and the registration statement (No. 333-179080) on Form S-3, of Jazz Pharmaceuticals plc of our reports dated February 25, 2014, with respect to the consolidated balance sheets of Jazz Pharmaceuticals plc as of December 31, 2013 and 2012, and the related consolidated statements of income, comprehensive income, shareholders’ equity, and cash flows for each of the years in the two-year period then ended, and the related financial statement schedule, and the effectiveness of internal control over financial reporting as of December 31, 2013, which reports appear in the December 31, 2013 annual report on Form 10-K of Jazz Pharmaceuticals plc.
/s/ KPMG
Dublin, Ireland
February 25, 2014